**Background of CARM1 Antibody**
CARM1 (Coactivator-Associated Arginine Methyltransferase 1), also known as PRMT4. is a member of the protein arginine methyltransferase (PRMT) family. It catalyzes the methylation of arginine residues on histones and non-histone proteins, playing a critical role in transcriptional regulation, chromatin remodeling, and cellular signaling. CARM1 functions as a coactivator for nuclear receptors (e.g., estrogen and androgen receptors) and transcription factors, facilitating gene activation by modifying histones (e.g., H3R17 and H3R26 methylation) and methylating transcriptional regulators like p300 and MED12.
CARM1 antibodies are essential tools for studying its expression, localization, and molecular interactions. They are widely used in techniques such as Western blotting, immunoprecipitation, and immunofluorescence to investigate CARM1's role in development, differentiation, and disease. Dysregulation of CARM1 is linked to cancers, inflammatory disorders, and metabolic syndromes, making it a potential therapeutic target. Antibodies specific to CARM1 help validate its involvement in pathways like the p53 network, Wnt/β-catenin signaling, and immune responses. Researchers rely on these antibodies to explore CARM1's dual role as an oncogene or tumor suppressor, depending on cellular context, and its impact on splicing, cell cycle, and apoptosis. Validated CARM1 antibodies are crucial for advancing studies in epigenetics and disease mechanisms.